Biohaven Ltd. vs. Eli Lilly & Co.
Biohaven Ltd. and Eli Lilly & Co. are evenly matched on the factors we track — the better pick depends on what you're optimizing for.
Size & Scale
| BHVN | LLY | |
|---|---|---|
| Market Cap | $2.15 billion | $1.05 trillion |
| Revenue (TTM) | $859.68 million | $79.67 billion |
| Net Income (TTM) | $-930,691,000 | $26.71 billion |
LLY leads on 3 of 3 size & scale factors.
Valuation
| BHVN | LLY | |
|---|---|---|
| P/E Ratio | — | 39.77 |
| Price / Book | -2.67 | 31.14 |
| Price / Sales | 2.50 | 13.24 |
BHVN leads on 2 of 2 valuation factors.
Profitability
| BHVN | LLY | |
|---|---|---|
| Net Margin | -108.26% | 33.53% |
| Return on Equity | 115.53% | 78.84% |
BHVN and LLY split the profitability factors evenly.
Dividend
| BHVN | LLY | |
|---|---|---|
| Dividend Yield | — | 0.58% |
| Payout Ratio | — | 23.23 |
BHVN and LLY split the dividend factors evenly.
Risk & Sentiment
| BHVN | LLY | |
|---|---|---|
| Short Interest | 0.79% | 1.29% |
BHVN leads on 1 of 1 risk & sentiment factors.
Dig deeper: BHVN overview, BHVN financials, LLY overview, LLY financials.
Comparisons use delayed, cached fundamental data and cover only the factors shown. For informational purposes only — not investment advice.